Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.59 |
| ▸ | FYN | P06241 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12682412 | 0.83 | LCK (0.62) | LCKFYNMAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL24162896 | 0.83 | POLB (0.63) | LCKFYNLMNASMN1; SMN2KDM4E | |
| SCHEMBL24162970 | 0.81 | HPGD (0.57) | LCKFYNLMNAKDM4EKMT2A | |
| SCHEMBL17602018 | 0.81 | LCK (0.65) | LCKFYNLMNAKDM4ETSHR | |
| SCHEMBL24162935 | 0.80 | CYP1A2 (0.52) | LCKFYNLMNASMN1; SMN2KDM4E | |
| SCHEMBL20944571 | 0.79 | LCK (0.54) | LCKFYNMAPTSMN1; SMN2KDM4E | |
| SCHEMBL20944628 | 0.79 | LCK (0.54) | LCKFYNMAPTSMN1; SMN2KDM4E | |
| SCHEMBL20944570 | 0.79 | LCK (0.54) | LCKFYNMAPTSMN1; SMN2KDM4E | |
| SCHEMBL23015581 | 0.78 | ACHE (0.70) | LMNAMAPTSMN1; SMN2RAB9AL3MBTL1 | |
| SCHEMBL20944671 | 0.77 | POLB (0.70) | LCKFYNMAPTKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2356110-B1 | QUINAZOLINAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-01-06 | — | — | EP | disclosed |
| EP-2356110-B1 | QUINAZOLINAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-01-06 | — | — | EP | disclosed |
| US-8546565-B2 | Quinazolinamide derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8546565-B2 | Quinazolinamide derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8546565-B2 | Quinazolinamide derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2013-10-01 | — | — | US | disclosed |
| CN-102245596-A | Quinazolinamide derivatives | MERCK PATENT GMBH | 2011-11-16 | — | — | CN | disclosed |
| US-20110245225-A1 | QUINAZOLINAMIDE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTING (DE) | 2011-10-06 | — | — | US | disclosed |
| US-20110245225-A1 | QUINAZOLINAMIDE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTING (DE) | 2011-10-06 | — | — | US | disclosed |
| US-20110245225-A1 | QUINAZOLINAMIDE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTING (DE) | 2011-10-06 | — | — | US | disclosed |
| EP-2356110-A1 | QUINAZOLINAMIDE DERIVATIVES | Merck Patent GmbH (DE) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010066324-A1 | QUINAZOLINAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010066324-A1 | QUINAZOLINAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245225-A1 | QUINAZOLINAMIDE DERIVATIVES | HSP90AB1, HSP90AA1, HSP90B1 | LCK 1809/4885FYN 3628/4885LMNA 3355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.